Tubulointerstitial nephritis and uveitis syndrome (TINU) following COVID-19 vaccination

Chen, Kevin W; Chang, Eileen L; Sheridan, Alice M.; Papaliodis, George N.

doi:10.1016/j.ajoc.2023.101869

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 Therefore, not only infection itself but also COVID-19 vaccines may cause autoimmune diseases such as TINU. 26 , 29 However, none of the cases in our series had a history of COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 67%

“…In addition to SARS-CoV-2 infection, cases of uveitis or nephritis developing after COVID-19 vaccination have been reported in the literature. 26 , 27 , 28 Chen et al 26 recently reported a case of TINU with bilateral anterior uveitis after receiving the COVID-19 mRNA vaccine. In a report of TINU cases during the COVID-19 pandemic, 2 out of 18 patients were reported to have received the COVID-19 vaccine before the onset of ocular symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tubulointerstitial Nephritis and Uveitis Syndrome During the COVID-19 Pandemic: A Case Series

Özdemir Yalçınsoy,

Güngör,

Karakaya

et al. 2024

tjo

View full text Add to dashboard Cite

Objectives: To report the ocular findings, laboratory results, and management of patients with tubulointerstitial nephritis and uveitis syndrome (TINU), whose numbers increased during the 2019 coronavirus disease (COVID-19) pandemic. Materials and Methods: Demographic characteristics, ophthalmic examination findings, laboratory results including polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), serum SARS-CoV-2 immunoglobulin G (IgG) antibody, and treatment of patients diagnosed with TINU between March 2020 and March 2022 were evaluated retrospectively. Results: The study included 19 eyes of 10 patients (6 female/4 male). The mean age was 13.5±2.4 years (range: 8-16 years). The mean follow-up duration was 13.5±6.1 months (range: 6-24 months). All patients presented with anterior uveitis. Anterior uveitis was bilateral in 9 patients (90%) and unilateral in 1 patient (10%). Posterior segment findings were normal in 8 patients (80%), and bilateral optic disc edema was observed in only 2 patients (20%). None of the patients had a previous SARS-CoV-2 infection and/or vaccination history. The SARS-CoV-2 PCR test was negative in all patients at presentation. The SARS-CoV-2 IgG antibody test was reactive in 7 patients (70%). Recurrent uveitis developed in 8 patients (80%) during follow-up. Systemic immunomodulatory therapy was required for the control of ocular inflammation in 7 patients (70%) with severe uveitis flare-ups. Conclusion: TINU is a multisystemic autoimmune disease, especially in response to environmental triggering factors such as viral infections. Although TINU is a rare disease, the number of cases increased during the COVID-19 pandemic. SARS-CoV-2 antibodies were detected at a significant rate of 70% in these patients, who did not have a history of SARS-CoV-2 infection and vaccination. Previous asymptomatic SARS-CoV-2 infection in children may be a triggering factor in the development of TINU.

show abstract

Section: Discussionmentioning

confidence: 67%